{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T04:52:30Z","timestamp":1764046350264,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":2626,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.breast.2012.04.008","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T20:20:16Z","timestamp":1337718016000},"page":"544-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis"],"prefix":"10.1016","volume":"21","author":[{"given":"Xiaoyan","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2012.04.008_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2407-6-179","article-title":"Clinical management of women with metastatic breast cancer: a descriptive study according to age group","volume":"6","author":"Manders","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2012.04.008_bib2","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2012.04.008_bib3","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.23775","article-title":"Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database","volume":"113","author":"Hatoum","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2012.04.008_bib4","first-page":"653","article-title":"Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer","volume":"18","author":"Heras","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.breast.2012.04.008_bib5","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.clinthera.2009.05.009","article-title":"Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials","volume":"31","author":"Machado","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.breast.2012.04.008_bib6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1634\/theoncologist.11-7-841","article-title":"Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial","volume":"11","author":"Carteni","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2012.04.008_bib7","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2012.04.008_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2407-11-29","article-title":"Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark","volume":"11","author":"Jensen","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2012.04.008_bib9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","article-title":"Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years","volume":"10","author":"Guarneri","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2012.04.008_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00044011-200626060-00002","article-title":"Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial","volume":"26","author":"Pecherstorfer","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.breast.2012.04.008_bib11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12032-008-9045-3","article-title":"Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases","volume":"25","author":"Dincer","year":"2008","journal-title":"Med Oncol"},{"key":"10.1016\/j.breast.2012.04.008_bib12","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1200\/JCO.2001.19.14.3434","article-title":"Safety and efficacy of bisphosphonates beyond 24 months in cancer patients","volume":"19","author":"Ali","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2012.04.008_bib13","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/cncr.24119","article-title":"Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients","volume":"115","author":"Walter","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2012.04.008_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nrendo.2010.195","article-title":"Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review","volume":"7","author":"Migliorati","year":"2011","journal-title":"Nat Rev Endocrinol"},{"year":"2006","series-title":"Common terminology criteria for adverse events (CTCAE). Version 3.0","author":"Cancer Therapy Evaluation Program","key":"10.1016\/j.breast.2012.04.008_bib15"},{"key":"10.1016\/j.breast.2012.04.008_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.breast.2012.04.008_bib17","first-page":"354","article-title":"ASBMR Task Force. Summary of ASBMR Task Force on ONJ","volume":"7","author":"Burr","year":"2007","journal-title":"J\u00a0Musculoskelet Neuronal Interact"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2012.04.008_bib18","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.3816\/CBC.2007.s.002","article-title":"Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer","volume":"7","author":"Lipton","year":"2007","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2012.04.008_bib19","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2012.04.008_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3816\/CBC.2005.n.014","article-title":"Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials","volume":"6","author":"Gordon","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2012.04.008_bib21","article-title":"Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan","author":"Henk","year":"2011","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.breast.2012.04.008_bib22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/SPC.0b013e32833d303b","article-title":"Updates on osteonecrosis of the jaw","volume":"4","author":"Yamashita","year":"2010","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.breast.2012.04.008_bib23","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(06)70726-4","article-title":"Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment","volume":"7","author":"Migliorati","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2012.04.008_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2012.04.008_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.breast.2012.04.008_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00044011-200626010-00006","article-title":"Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience","volume":"26","author":"McLachlan","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.breast.2012.04.008_bib27","first-page":"139","article-title":"Aging and osteoporosis in breast and prostate cancer","volume":"61","author":"Vander Walde","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2012.04.008_bib28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-0981-1","article-title":"Prognostic factors for skeletal complications from metastatic bone disease in breast cancer","volume":"123","author":"Brown","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2012.04.008_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/1471-2407-10-423","article-title":"Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain","volume":"10","author":"Koizumi","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2012.04.008_bib30","article-title":"Potential anticancer properties of bisphosphonates: insights from preclinical studies","author":"Cl\u00e9zardin","year":"2011","journal-title":"Anticancer Agents Med Chem"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097761200080X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097761200080X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:30:24Z","timestamp":1760776224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097761200080X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S096097761200080X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2012.04.008","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2012.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}